# Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

> **NCT06081673** · PHASE2 · RECRUITING · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 72 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Penpulimab injection
- **DRUG:** cisplatin
- **DRUG:** albumin-paclitaxel

## Key facts

- **NCT ID:** NCT06081673
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-30
- **Primary completion:** 2024-12-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2023-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06081673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06081673, "Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06081673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*